French drug giant Sanofi-Aventis has set its sights on developing China as its Asian R&D hub, unveiling plans for a significant expansion of its clinical research unit in Shanghai.
Merck & Co plans to cut 7,200 jobs, joining the growing list of big pharma firms enacting restructuring measures in the face of falling earnings and an uncertain market future.
The pharmaceutical industry must adapt its processes and strategies to cope with a new, tougher operating environment, according to Stefan Borgas, CEO of Lonza.
India’s reputation as a base for quality, low-cost drug manufacture has proved irresistible for yet another big pharma company with Japan’s Eisai unveiling plans for a new production and R&D facility.
Pfizer and Schering-Plough have both exceeded their earnings estimates, although this was largely underpinned by favourable exchange rates and low expectations.
US FDA approval for Teva’s transdermal fentanyl patch ushers the Israeli generics giant into the potentially lucrative but often problematic chronic pain therapy sector.
Bend Research is offering companies some of the drug delivery formulation expertise and technologies it developed during its 23 year collaboration with Pfizer.
Data analysis may be the next aspect of the drug industry to be outsourced if the new virtual drug development network created by GSK and UK software firm InforSense is any indication.
Covidien hopes that a $100m (€74m) expansion of facilities at its production hub in St Louis, Missouri, US will boost efficiency and cut the time it takes to bring products to market.
The European Parliament has voted in favour of incorporating the United Nations’ (UN) Globally Harmonised System (GHS) for chemical packaging into EU law.
Wyeth Medica, an Irish subsidiary of US drugmaker Wyeth, plans to cut 250 jobs at its manufacturing plant in Newbridge, County Kildare, according to media reports.
A new avenue of inquiry has been opened in the investigation into the US Food and Drug Administration’s (FDA) ability and commitment to protect the nation’s citizens from unsafe drugs.
US President George W Bush has signed a bill under which counterfeiters can be sentenced to life imprisonment if their crime causes the death of an individual.
US drugmaker Par Pharmaceuticals is wielding the axe at its generics division, cutting 190 jobs and refocusing its R&D efforts on the completion of its current roster of product candidates
China’s WuXi PharmaTech has reported a below par set of unaudited third quarter results and has cut its full-year expectations blaming the current economic climate’s impact on R&D spending within the sector.
in-PharmaTechnologist.com presents its latest round up of developments in drug delivery, including Philips first foray into drug delivery and a licensing deal for 3M.
Bilcare, Patheon, Pierre Fabre and Catalent were among the winners at the 2008 European Outsourcing awards, held during this year’s CPhI conference in Frankfurt, Germany.
Packaging firm Chesapeake has become a visible casualty of the current economic climate, with the New York Stock Exchange (NYSE) suspending trading of its shares.
Ahead of the “open house” at its facility in Monteriggioni, Siena, Italian machining specialist Marchesini spoke with in-PharmaTechnologist.com about the new plant and its role in the firm's offering to the drug industry.
in-PharmaTechnologist.com’s latest round up of developments in drug delivery includes Critical Pharmaceuticals’ sustained release hGH, Phase III results for AP Pharma and nanodiamonds.
Eli Lilly has agreed to acquire ImClone for $6.5bn and in doing so appears to have snatched the biotech away from Bristol-Myers Squibb (BMS), which first tabled a bid back in July.
Two chemical company directors have been sentenced for not notifying authorities that their company produced a substance controlled under the Chemical Weapons Convention (CWC).
in-PharmaTechnologist.com’s latest round up of products launched in the pharmaceutical manufacturing sector includes new offerings from Malvern, Caen, Finesse and Bausch.
Pfizer is shifting its research focus to those diseases where its sees the potential for the biggest treatment improvements and profits, while dropping eight disease areas including cholesterol.
Good Products and Adlib Software have teamed up to create a streamlined and compliant regulatory document management system for the pharmaceutical industry.
in-PharmaTechnologist.com’s latest round up of products launched in the pharmaceutical manufacturing sector includes new offerings from Premier Pneumatics, GE Healthcare and WaterSep.
Ranbaxy’s antiretrovirals zidovudine, lamivudine, and nevirapine have been removed from PEPFAR’s list of approved products until ongoing GMP problems at two of the firm’s Indian manufacturing plants are resolved.
Teva and Kowa have set their sights on Japan’s $4.6bn (€3.1bn) generics market with their development and manufacturing joint venture Teva-Kowa Pharma.
UK-based Melbourn Scientific is now offering an integrated package of formulation, method development, analysis and short-run clinical manufacture services to industrial clients.
Pharmaceutical companies on both sides of the Atlantic are facing a particularly difficult time over the next 12 to 18 months, according to a report by financial research and analysis company Moody’s.
in-PharmaTechnologist.com’s periodic round-up of developments in the pharmaceutical manufacturing space includes news on MannKind, Nycomed, ABS and Tris.
A domino effect appears to have been started by the FDA blocking Ranbaxy imports, with other regulatory bodies paying close attention to the generics giant.
Sanofi-Aventis’ €1.8bn ($2.6bn) offer for Czech generics firm Zentiva has been unanimously accepted by the latter firm’s board after four months of wrangling that has seen the bid increase by 9.5 per cent.
Germany-based Diapharm has launched a service allowing pharmaceutical manufacturers to perform joint third-party audits of active pharmaceutical ingredients (APIs).
Massachusetts needs to do more to produce workers for its life sciences industry if it is to avoid a skills shortage in years to come, according to research.
Outsourcing-Pharma.com presents its latest round-up of new appointments, employment moves and personnel news in the pharmaceutical contract services sector.
in-PharmaTechnologist.com's latest round-up of developments in pharmaceutical manufacturing features news of the world’s “biggest pharmaceutical allergen production unit”, Lentigen’s relocation and a cytotoxic robot.
APP Pharmaceuticals has bought additional facilities at a site in Grand Island, New York seizing the opportunity created by Astellas Manufacturing’s decision to shift production of its dermatitis drug Protopic to Japan.